With Dicerna's NASH Asset, Boehringer Found What It Was Looking For
In eyeing NASH, the firms both zeroed in on the same target, considered inaccessible to traditional modalities. The deal gives BI an RNAi approach, joining its Phase II anti-inflammatory candidate for NASH.
You may also be interested in...
Sanofi and Regeneron terminate the immuno-oncology partnership signed in 2015, but will continue to collaborate on Libtayo. Biogen signs a pair of partnerships in CNS disorders, with C4 and Skyhawk, and more deals from the first day of the J.P. Morgan conference.
Dicerna CEO tells Scrip the companies talked for two years and the collaboration came together as new Lilly R&D leadership looked to add novel approaches. Milestone fees of $350m per target for 10 or more targets value the deal at $3.7bn.
Away from the pricing pressures, reimbursement battles and problems of patent expiries in its home continent, the German major is counting on the US and China to provide the best opportunities for future growth.